Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
These findings provide comparative dermatologic safety evidence to inform incretin-based therapy selection in routine clinical practice
Eligibility criteria include defined BMI thresholds and the presence of at least one weight-related comorbidity
It's not covered by standard 503A/503B compounding frameworks applicable to shortage drugs
The announcement reinforces Altimmunes ongoing efforts to position pemvidutide within the broader GLP-1 and metabolic disease sector spanning obesity, liver disease and related cardiometabolic conditions
US$ 28.96
US$ 24.26
US$ 26.61
US$ 26.33
